February 06, 2017
1 min read

Orthocell to collaborate with DePuy Synthes on stem cell approach for degenerated tendons, ligaments

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Orthocell Limited announced a research collaboration agreement with DePuy Synthes Products Inc., part of the Johnson & Johnson Family of Companies, on its Ortho-ATI stem cell approach to regenerate degenerated tendons and ligaments. According to a press release, the partnership was facilitated by Johnson & Johnson Innovation.

Ortho-ATI is a non-surgical approach to treat chronic resistant tendon injuries that significantly impact activities of daily living. Ortho-ATI is offered in Australia and New Zealand for patients who have failed conservative treatment options and have ongoing symptoms. A collaborative, multicenter study on the approach is set to begin in the first quarter of 2017.

“This is [an] exciting partnership in the continued development of Ortho-ATI and provides significant external validation of this globally relevant technology,” Paul Anderson, managing director, said in the release.